On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation formally created MDL No. 3180, In Re: Dupixent (Dupilumab) Products Liability Litigation, centralizing federal Dupixent lawsuit claims before Judge Zahid N. Quraishi in the District of New Jersey. The order consolidated 15 pending cases from 12 federal districts, with 7 additional tag-along actions already identified. For the more than one million patients globally who have been prescribed Dupixent (dupilumab), this MDL formation marks a pivotal legal moment — and for those diagnosed with cutaneous T-cell lymphoma (CTCL) after taking the drug, it may open a critical window for compensation.
What Is MDL 3180 and Why Was It Created?
Multidistrict litigation is a federal procedural mechanism that consolidates similar lawsuits scattered across the country into a single court for coordinated pretrial proceedings. The JPML created MDL 3180 less than four weeks ago specifically to handle the growing volume of Dupixent lawsuit filings alleging that the blockbuster biologic caused, accelerated, or unmasked cutaneous T-cell lymphoma in patients who had no prior lymphoma history. You can review the JPML’s formal authority and procedures for MDL creation directly at uscourts.gov.
The JPML petition was originally filed on February 13, 2026, by three named plaintiffs — Wanda Nalls, John I. Mun, and Giovanni Fraioli — each alleging they developed CTCL following Dupixent treatment. Notably, both the plaintiffs and the defendants, Regeneron Pharmaceuticals and Sanofi, agreed that consolidation was appropriate — a relatively rare alignment in mass tort litigation. Their disagreement centered only on venue: plaintiffs preferred the Northern District of Georgia, while Regeneron and Sanofi pushed for the Southern District of New York. The JPML chose the District of New Jersey, citing judicial efficiency and Judge Quraishi’s availability and experience.
As of the MDL’s formation, no global settlement has been reached and no jury verdict has been returned. This litigation is in its earliest pretrial phase, meaning the discovery process — including document production from Regeneron and Sanofi — has not yet commenced in earnest. The next JPML hearing session is scheduled for July 30, 2026, in Asheville, North Carolina, where additional tag-along transfers are expected to be addressed, likely expanding the number of centralized cases significantly.
The Science Behind the Dupixent Lawsuit Claims
Dupixent (dupilumab) was first approved by the FDA in 2017 for moderate-to-severe atopic dermatitis (eczema). Since then, its approved indications have expanded to include asthma, chronic obstructive pulmonary disease (COPD), nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Dupixent works by blocking the IL-4 and IL-13 signaling pathways, which are central to Type 2 inflammatory responses. However, plaintiffs allege that this same immune-modulating mechanism may suppress the body’s natural T-cell surveillance, potentially allowing malignant T-cell clones to proliferate unchecked — a biological pathway that may explain the observed rise in CTCL diagnoses.
Seven epidemiologic studies have now linked Dupixent use to elevated T-cell lymphoma risk, and the data cited in the MDL 3180 JPML petition is striking. A 2024 retrospective cohort study published in the Journal of the American Academy of Dermatology found that Dupixent patients had more than a 300% increased risk of CTCL compared to untreated subjects. A 2025 cohort study in the European Respiratory Journal, examining asthma patients treated with Dupixent versus those on inhaled corticosteroids, found nearly a 400% increased risk of T-cell and NK-cell lymphomas overall — with increases of 450–500% specifically for CTCL, peripheral T-cell lymphoma (PTCL), and Mycosis fungoides/Sézary syndrome subtypes. A separate study published in Dermatologic Therapy calculated that Dupixent users with eczema face a 4.59x higher relative risk of CTCL compared to non-users.
One of the most concerning clinical complications underlying these Dupixent lawsuit claims is diagnostic delay. CTCL in its early stages can present with symptoms nearly identical to eczema — redness, scaling, itching, and thickened patches of skin. Because Dupixent is prescribed to treat eczema, patients whose eczema symptoms were actually early-stage CTCL may have had their cancer masked, misidentified, or left untreated for months or years. The FDA has already listed CTCL as a potential safety signal in its Adverse Event Reporting System (FAERS) and is currently evaluating whether formal regulatory action is warranted.
Key Statistics at a Glance
| Study / Source | Population Studied | Finding |
|---|---|---|
| Hasan I et al., J Am Acad Dermatol 2024 (cited in JPML Petition, MDL 3180) | Dupixent users vs. untreated eczema patients | >300% increased risk of CTCL |
| Sheng-Kai Ma K et al., Eur Respir J 2025 (cited in JPML Petition, MDL 3180) | Dupixent asthma patients vs. inhaled corticosteroid users | ~400% increased T-cell/NK-cell lymphoma risk; 450–500% for CTCL, PTCL, MF/SS subtypes |
| Dermatologic Therapy study (cited by Sokolove Law, 2026) | Dupixent eczema users vs. non-users | 4.59x higher relative risk of CTCL |
| JPML Petition, MDL 3180 | All qualifying epidemiologic studies reviewed | 7 separate studies link Dupixent to elevated T-cell lymphoma risk |
| Sokolove Law (2026) | CTCL cases among Dupixent users | Majority of diagnoses reported within one year of starting the drug |
What Plaintiffs Allege Against Regeneron and Sanofi
At the core of every Dupixent lawsuit consolidated into MDL 3180 is a failure-to-warn allegation. Plaintiffs contend that Regeneron and Sanofi knew or should have known — based on clinical signals, post-market surveillance data, and emerging epidemiologic research — that Dupixent carried a meaningful risk of inducing or accelerating CTCL. Despite this, they allegedly failed to adequately warn patients and prescribing physicians of this potential cancer risk. If those warnings had been provided, patients argue, they or their doctors would have weighed the risks differently and potentially chosen alternative therapies.
Beyond failure-to-warn, the complaints raise claims sounding in strict products liability (design defect), negligence, and in some cases fraudulent concealment. Dupixent is one of the highest-revenue biologics in the United States, generating billions of dollars annually for Sanofi and Regeneron — a financial backdrop that plaintiffs say creates a powerful motive to minimize or delay disclosure of safety risks. For individuals now living with a CTCL diagnosis, the human cost is measured not just in medical bills and lost income, but in the profound disruption of a cancer diagnosis that may have been preventable or at least anticipated. Understanding the potential value of such claims is where a medical malpractice calculator can help patients begin to frame what compensation might look like in a defective drug context.
The JPML also left open the possibility of expanding MDL 3180 to include other T-cell lymphoma subtypes beyond CTCL through conditional transfer orders. This signals that the panel anticipates the litigation universe will grow as more patients receive diagnoses and more scientific data emerges.
Who May Be Eligible to File a Dupixent Lawsuit
If you or a family member took Dupixent and were later diagnosed with CTCL or a related T-cell lymphoma subtype, you may have a viable claim in MDL 3180. Based on the qualifying criteria being investigated in connection with this litigation, potential plaintiffs generally meet the following threshold criteria according to information from Nolo.com’s mass tort legal guide:
- Duration of use: Took Dupixent (dupilumab) for at least one month under a valid prescription
- Diagnosis timing: Received a diagnosis of CTCL, Mycosis fungoides, Sézary syndrome, peripheral T-cell lymphoma, or another qualifying T-cell lymphoma subtype after beginning Dupixent treatment
- No prior lymphoma history: Had no pre-existing lymphoma or leukemia diagnosis before starting Dupixent
- Approved indication: Was prescribed Dupixent for any FDA-approved condition including atopic dermatitis, asthma, COPD, nasal polyps, eosinophilic esophagitis, or prurigo nodularis
Because the majority of CTCL diagnoses among Dupixent users have been reported within the first year of starting the drug, patients who took Dupixent even for a relatively brief period should not assume they are ineligible simply because their use was short-term. Statutes of limitations vary by state, and with MDL 3180 still in its earliest stages, timing matters. For those evaluating whether to proceed with a claim, using a personal injury settlement calculator can provide a general orientation to how courts value serious injury claims before you speak with legal counsel.
Families who lost a loved one to a T-cell lymphoma potentially linked to Dupixent may also have standing to pursue wrongful death claims within the MDL framework. The eligibility criteria and procedural pathways for survivor claims are distinct from individual personal injury filings and require careful legal analysis specific to the decedent’s prescription history and cause of death.
Frequently Asked Questions About the Dupixent Lawsuit
What is MDL 3180 and how does it affect my Dupixent lawsuit?
MDL No. 3180, created by the JPML on June 4, 2026, is a federal multidistrict litigation that centralizes all qualifying Dupixent lawsuit claims in the District of New Jersey before Judge Zahid N. Quraishi. If you file a federal Dupixent lawsuit alleging CTCL or related T-cell lymphoma injuries, your case will likely be transferred to this MDL for coordinated pretrial proceedings — including discovery and bellwether trials — while you retain your individual case and any eventual right to your own trial or settlement.
What cancer is linked to Dupixent in these lawsuits?
The primary cancer at issue in the Dupixent lawsuit MDL is cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma that originates in the skin. Specific subtypes involved include Mycosis fungoides, Sézary syndrome, and peripheral T-cell lymphoma (PTCL). The JPML left open the possibility of including additional T-cell lymphoma subtypes through conditional transfer orders as the science continues to develop.
How strong is the scientific evidence linking Dupixent to CTCL?
As of 2026, seven separate epidemiologic studies have found elevated T-cell lymphoma risk associated with Dupixent use. A 2024 study in the Journal of the American Academy of Dermatology found a greater than 300% increased CTCL risk, while a 2025 European Respiratory Journal study found nearly 400% elevated T-cell lymphoma risk in asthma patients — with 450–500% increases for specific subtypes including CTCL and Mycosis fungoides/Sézary syndrome. The FDA has listed CTCL as a potential safety signal in its FAERS database and is currently evaluating the need for regulatory action.
Do I qualify to file a Dupixent lawsuit if I only took the drug briefly?
Potentially yes. The baseline eligibility threshold being investigated is at least one month of Dupixent use followed by a CTCL or qualifying T-cell lymphoma diagnosis, with no prior lymphoma history. Because a significant portion of diagnoses have emerged within the first year of starting Dupixent, short-term users are not automatically excluded. You should document your prescription history, diagnosis date, and medical records and consult qualified legal counsel to assess your specific circumstances within the MDL 3180 framework.
Has there been any settlement in the Dupixent lawsuit MDL yet?
No. As of the MDL’s formation on June 4, 2026, no global settlement, individual settlement fund, or jury verdict has been reached in the Dupixent lawsuit litigation. The cases are in the earliest stages of pretrial proceedings. MDLs of this complexity typically move through discovery, expert designation, and bellwether trials before settlement discussions mature — a process that can take several years. The next JPML hearing addressing tag-along transfers is scheduled for July 30, 2026, in Asheville, North Carolina, which may expand the MDL’s scope.
This article is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding the specific facts of your potential Dupixent lawsuit claim.
Related reading: Psychiatric Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.